Chronic Cluster Headache Clinical Trial
— CHRONICLEOfficial title:
Interventional, Open-label, Fixed-dose Multiple Administration Study to Evaluate Long-term Treatment With Eptinezumab in Patients With Chronic Cluster Headache
Verified date | July 2023 |
Source | H. Lundbeck A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main goal of this trial is to inform about long-term safety and tolerability of eptinezumab in participants with chronic cluster headache.
Status | Completed |
Enrollment | 131 |
Est. completion date | June 29, 2023 |
Est. primary completion date | June 29, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - The participant has a diagnosis of cCH as defined by International Headache Society (IHS) International Classification of Headache Disorders third edition (ICHD-3) classification with a history of cCH of at least 12 months prior to the Screening Visit. - The participant has a medical history of onset of cluster headache at =50 years of age. - The participant has an adequately documented record of previous abortive, transitional and preventive medication use for cCH, for at least 12 months prior to the Screening Visit. - The participant is able to distinguish cluster headache attacks from other headaches (such as tension-type headaches, migraine). Exclusion Criteria: - The participant has experienced failure on a previous treatment targeting the calcitonin gene-related peptide (CGRP) pathway (anti-CGRP monoclonal antibodies [mAbs] and gepants). - The participant has confounding and clinically significant pain syndromes (for example, fibromyalgia, complex regional pain syndrome). - The participant has a history or diagnosis of chronic tension-type headache, hypnic headache, hemicrania continua, new daily persistent headache, chronic migraine or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), recurrent painful ophthalmoplegic neuropathy, migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or longer than 1 hour). - Participants with a lifetime history of psychosis, bipolar mania, or dementia. Participants with other psychiatric conditions whose symptoms are not controlled or who have not been adequately treated for a minimum of 6 months prior to Screening Visit. - The participant has attempted suicide or is, at Screening Visit, at significant risk of suicide. - The participant has a history of clinically significant cardiovascular disease, including uncontrolled hypertension, vascular ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism). Other inclusion and exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Denmark | Rigshospitalet Glostrup | Glostrup | Hovedstaden |
Denmark | Hospitalsenhed Midt og Regionshospitalet Viborg | Viborg | Midtjylland |
Finland | Terveystalo Ruoholahti | Helsinki | Southern Finland |
Finland | Terveystalo Turku Pulssi | Turku | Western Finland |
France | Hôpital Pierre Wertheimer | Bron | Rhône |
France | Hôpital Roger Salengro | Lille | Nord |
France | Hôpital de la Timone | Marseille Cedex 5 | Provence Alpes Cote d'Azur |
France | Hôpital Cimiez | Nice Cedex 1 | Côte-d'Or |
France | Hôpital Lariboisière | Paris | Île-de-France |
France | Centre Hospitalier Universitaire de Saint-Étienne | Saint-Priest-en-Jarez | Rhône |
Germany | Charité Campus Mitte | Berlin | |
Germany | Kopfschmerzzentrum Frankfurt | Frankfurt/ Main | Hessen |
Italy | IRCCS Istituto Delle Scienze Neurologiche di Bologna | Bologna | |
Italy | Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Fondazione Istituto Neurologico Car... | Milano | Milan |
Italy | Fondazione Mondino - Istituto Neurologico Nazionale a Carattere Scientifico IRCCS | Pavia | |
Italy | Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - San Raffaele Pisana | Rome | Roma |
Italy | Ospedale Molinette - Clinica Neurologica II - Centro Cefalee | Turin | |
Netherlands | Brain Research Center - Amsterdam | Amsterdam | Noord-Holland |
Netherlands | Canisius-Wilhelmina Ziekenhuis | Nijmegen | Gelderland |
Spain | Hospital Universitari Vall d'Hebron | Barcelona | |
Spain | Hospital Universitario Marques de Valdecilla | Santander | Cantabria |
Spain | Hospital Universitario Virgen del Rocío | Sevilla | |
Spain | Hospital Clínico Universitario de Valencia | València | |
Spain | Hospital Clínico Universitario de Valladolid | Valladolid | |
United Kingdom | The Walton Centre NHS Foundation Trust | Liverpool | England |
United Kingdom | King's College Hospital NHS Foundation Trust | London | England |
United States | Dent Neurologic Institute - Amherst | Amherst | New York |
United States | Michigan Headache and Neurological Institute | Ann Arbor | Michigan |
United States | Cleveland Clinic - Neurological Institute | Cleveland | Ohio |
United States | Thomas Jefferson University Hospital - Center City Campus | Philadelphia | Pennsylvania |
United States | New England Institute for Neurology and Headache | Stamford | Connecticut |
Lead Sponsor | Collaborator |
---|---|
H. Lundbeck A/S |
United States, Denmark, Finland, France, Germany, Italy, Netherlands, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Adverse Events | From the day of first dose of study drug (Baseline [Week 0]) up to Week 56 | ||
Secondary | Conversion From Chronic Cluster Headache (cCH) to Episodic Cluster Headache: Number of Participants With No Cluster Headache Attacks for =3 Consecutive Months (=13 Consecutive Weeks) | Baseline (Week 0) to Week 48 | ||
Secondary | Change From Baseline in Weekly Number of Times an Abortive Therapy (Oxygen and/or Triptans) Was Used, Averaged Over the First 4 Weeks After Each Infusion | Baseline (Week 0), Weeks 1 to 4, 13 to 16, 25 to 28, and 37 to 40 | ||
Secondary | Change From Baseline in the Average Number of Weekly Attacks, Averaged Over the First 4 Weeks After Each Infusion | Baseline (Week 0), Weeks 1 to 4, 13 to 16, 25 to 28, and 37 to 40 | ||
Secondary | Change From Baseline in the 5-Point Self-Rating Pain Severity Scale, Averaged Over the First 4 Weeks After Each Infusion | Baseline (Week 0), Weeks 1 to 4, 13 to 16, 25 to 28, and 37 to 40 | ||
Secondary | Response: Number of Participants With =30% Reduction From Baseline in Number of Weekly Attacks Averaged Over the First 4 Weeks After Each Infusion | Weeks 1 to 4, 13 to 16, 25 to 28, and 37 to 40 | ||
Secondary | Response: Number of Participants With =50% Reduction From Baseline in Number of Weekly Attacks Averaged Over the First 4 Weeks After Each Infusion | Weeks 1 to 4, 13 to 16, 25 to 28, and 37 to 40 | ||
Secondary | cCH Remission: Number of Participants With No Cluster Headache Attacks For =1 Month (5 Consecutive Weeks) | Baseline (Week 0) to Week 48 | ||
Secondary | cCH Remission: Number of Participants With No Cluster Headache Attacks For =1 Month (5 Consecutive Weeks Between the First and Second Infusion) | Baseline (Week 0) to Week 12 | ||
Secondary | cCH Remission: Number of Participants With No Cluster Headache Attacks For =1 Month (5 Consecutive Weeks Between the Second and Third Infusion) | Week 12 to Week 24 | ||
Secondary | cCH Remission: Number of Participants With No Cluster Headache Attacks For =1 Month (5 Consecutive Weeks Between the Third and Fourth Infusion) | Week 24 to Week 36 | ||
Secondary | cCH Remission: Number of Participants With No Cluster Headache Attacks For =1 Month (5 Consecutive Weeks Within the First 12 Weeks After the Fourth Infusion) | Week 36 to Week 48 | ||
Secondary | Number of Participants who Received a Transitional Therapy During the Treatment Period | Week 0 to Week 48 | ||
Secondary | Patient Global Impression of Change (PGIC) Score | Baseline (Week 0) up to Week 48 | ||
Secondary | Change From Baseline in Sleep Impact Scale (SIS) Domain Scores Over the Time | Baseline (Week 0) up to Week 40 | ||
Secondary | Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Score at Weeks 4, 16, 28, 40 and 48 | Baseline (Week 0) , Weeks 4, 16, 28, 40 and 48 | ||
Secondary | Health Care Resources Utilization (HCRU) Score | Baseline (Week 0) , Weeks 4, 16, 28, 40 and 48 | ||
Secondary | Change From Baseline in the Work Productivity Activity Impairment: General Health Second Version (WPAI:GH2.0) Sub-Scores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Weeks 4, 16, 28, 40 and 48 | Baseline (Week 0) , Weeks 4, 16, 28, 40 and 48 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02462395 -
Anodal Transcranial Direct Stimulation (tDCS) for the Treatment of Chronic Cluster Headache
|
Phase 2/Phase 3 | |
Recruiting |
NCT01701245 -
Prevention and Acute Treatment of Chronic Cluster Headache Compared to Standard of Care
|
Phase 2 | |
Completed |
NCT01151631 -
Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache
|
Phase 3 | |
Recruiting |
NCT06124534 -
Bilateral Occipital Nerve Field Stimulation for the Treatment of dtCCH
|
N/A | |
Unknown status |
NCT00399243 -
Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache
|
Phase 4 | |
Recruiting |
NCT05868044 -
REsponse to Combined SONS and ONS in Chronic Cluster headachE
|
N/A | |
Completed |
NCT01616511 -
Pathway CH-1 Long-Term Follow-Up
|
N/A | |
Completed |
NCT01359631 -
Cephalic Vascular Recording Upon SPG Stimulation
|
N/A | |
Completed |
NCT02438826 -
A Study of Galcanezumab in Participants With Chronic Cluster Headache
|
Phase 3 | |
Completed |
NCT02510729 -
SPG Neurostimulation in Cluster Patients
|
N/A | |
Active, not recruiting |
NCT02168764 -
Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache
|
N/A | |
Completed |
NCT02797951 -
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
|
Phase 3 | |
Not yet recruiting |
NCT05477459 -
LSD to Improve Cluster Headache Impact Trial
|
Phase 2 | |
Completed |
NCT03244735 -
Efficacy of Modified Atkins Ketogenic Diet in Chronic Cluster Headache: a Prospective Case Series
|
N/A | |
Terminated |
NCT02964338 -
A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)
|
Phase 3 | |
Completed |
NCT01255813 -
Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache
|
N/A | |
Active, not recruiting |
NCT05023460 -
Treatment of Chronic Cluster Headache With TENS and ONS
|
N/A |